Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

LocanaBio

Main focus: Next-generation editing of RNA to treat genetic diseases

Company stage: Pre-clinical

Diseases: amyotrophic lateral sclerosis (ALS), myotonic dystrophy type 1 (DM1), Huntingtons disease, retinal diseases

Genome editing tool: CRISPR-Cas13d

Funding stage: Private

Location: San Diego, CA, USA

Website: https://locanabio.com/

Pipeline: https://locanabio.com/pipeline/

LocanaBio is developing next-generation RNA-editing technologies, applying its proprietary CRISPR-based CORRECTX^™platform to do so. The company focuses on neuromuscular, neurodegenerative and ophthalmologic diseases, with multiple pre-clinical programmes currently under development.

Your Latest CMN News

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Gene-Editing Clinical Trial Updates - What's...

Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

Company: LocanaBio

Search CRISPR Medicine